NCT01122511

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration

Conditions

• Subfoveal Choroidal Neovascularization
• Age-Related Maculopathy

Interventions

Type	Name	Description
DRUG	700 ug dexamethasone	Intravitreal injection of 700 ug dexamethasone into study eye
BIOLOGICAL	ranibizumab	Intravitreal injection of ranibizumab into study eye
OTHER	sham	Sham needle-less injection administered in the study eye

Timeline

• Start date: 2010-08-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2010-05-13
• Last updated: 2012-09-05
• Results posted: 2012-09-05

Locations

2 sites across 1 country: United States